Xiao-hong Ding
Key Laboratory Of Breast Cancer In Shanghai
Shanghai, 200032, China
Shanghai, 200032, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancer.
Journal: Cell metabolism
Published: July 30, 2026
Phase separation of DDHD2 remodels lipid metabolism to dictate treatment sensitivity in luminal breast cancer.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 11, 2026
HEBP2-governed glutamine competition between tumor and macrophages dictates immunotherapy efficacy in triple-negative breast cancer.
Journal: Cell metabolism
Published: February 28, 2025
Comprehensive genomic profiling of triple-negative breast cancer metastases identifies role of PKD1 in immunotherapy resistance.
Journal: The Journal of clinical investigation
Published: November 18, 2024
Guanosine diphosphate-mannose suppresses homologous recombination repair and potentiates antitumor immunity in triple-negative breast cancer.
Journal: Science translational medicine
Published: January 03, 2024
The HLA-I landscape confers prognosis and antitumor immunity in breast cancer.
Journal: Briefings in bioinformatics
Published: November 08, 2023
Genomic alterations affecting tumor-infiltrating lymphocytes and PD-L1 expression patterns in triple-negative breast cancer.
Journal: Journal of the National Cancer Institute
Published: December 22, 2022
Bidirectional crosstalk between therapeutic cancer vaccines and the tumor microenvironment: Beyond tumor antigens.
Journal: Fundamental research
Published: November 07, 2021
Showing 1-9 of 9
Last Updated: 09/26/2026